Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Value of total tumor load as a clinical and pathological factor in the prognosis of breast cancer patients receiving neoadjuvant treatment. Comparison of three populations with three different surgical approaches: NEOVATTL Pro 3 Study.
Martín-Salvago MD, Sancho M, López-García MÁ, Cano Jiménez A, Pérez-Luque A, Alfaro L, Vieites B. Martín-Salvago MD, et al. Breast Cancer Res Treat. 2023 Jul;200(2):203-215. doi: 10.1007/s10549-023-06954-8. Epub 2023 May 23. Breast Cancer Res Treat. 2023. PMID: 37219637 Free PMC article.
Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study.
Vieites B, López-García MÁ, Martín-Salvago MD, Ramirez-Tortosa CL, Rezola R, Sancho M, López-Vilaró L, Villardell F, Burgués O, Fernández-Rodriguez B, Alfaro L, Peg V. Vieites B, et al. Among authors: martin salvago md. Clin Transl Oncol. 2021 Jul;23(7):1377-1385. doi: 10.1007/s12094-020-02530-4. Epub 2021 Jan 31. Clin Transl Oncol. 2021. PMID: 33517542 Free PMC article.
Validation of prognostic and predictive value of total tumoral load after primary systemic therapy in breast cancer using OSNA assay.
Bernet-Vegué L, Cantero-González C, Sancho de Salas M, Parada D, Perin T, Quintero-Niño Z, Vieites Pérez-Quintela B, Sánchez-Guzmán D, Castelvetere M, Hardisson Hernaez D, Martín-Salvago MD. Bernet-Vegué L, et al. Among authors: martin salvago md. Clin Transl Oncol. 2024 May;26(5):1220-1228. doi: 10.1007/s12094-023-03347-7. Epub 2023 Dec 9. Clin Transl Oncol. 2024. PMID: 38070048 Free PMC article.
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Among authors: martin salvago md. Clin Transl Oncol. 2008 Oct;10(10):646-53. doi: 10.1007/s12094-008-0265-y. Clin Transl Oncol. 2008. PMID: 18940745 Clinical Trial.
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, Carrasco E, Chacón I, García-Tapiador AM, Ortega-Granados AL, Martínez-Ortega E, Ribelles N, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Martínez J, Tortosa CR, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Among authors: martin salvago md. Am J Clin Oncol. 2010 Oct;33(5):432-7. doi: 10.1097/COC.0b013e3181b4eff9. Am J Clin Oncol. 2010. PMID: 19952716 Clinical Trial.
Redox status in the sentinel lymph node of women with breast cancer.
Ramírez-Expósito MJ, Urbano-Polo N, Dueñas B, Navarro-Cecilia J, Ramírez-Tortosa C, Martín-Salvago MD, Martínez-Martos JM. Ramírez-Expósito MJ, et al. Among authors: martin salvago md. Ups J Med Sci. 2017 Nov;122(4):207-216. doi: 10.1080/03009734.2017.1403522. Epub 2017 Dec 21. Ups J Med Sci. 2017. PMID: 29264992 Free PMC article.
Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. González-González A, et al. Among authors: martin salvago md. Clin Cancer Res. 2018 Nov 15;24(22):5697-5709. doi: 10.1158/1078-0432.CCR-17-3125. Epub 2018 Jul 16. Clin Cancer Res. 2018. PMID: 30012564
[Abdominal tumor and fever].
Martín Guerrero JM, Castro Laria L, Martín Salvago MD, Rivera Hueto F, Herrerías Gutiérrez JM. Martín Guerrero JM, et al. Among authors: martin salvago md. Rev Clin Esp. 2000 Apr;200(4):227-8. doi: 10.1016/s0014-2565(00)70612-6. Rev Clin Esp. 2000. PMID: 10857410 Spanish. No abstract available.
11 results